Home >> Medical Devices >> Food & Beverage >>

Cancer Diagnostics Market by Methods (Tumor Biomarker Tests, Imaging, Endoscopy, and Biopsy) for Blood Cancer, Breast Cancer, Colorectal Cancer (CRC), Lung Cancer, Other: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2014 - 2020

Published: Apr-2016 | Format: PDF | Zion | Number of pages: 110 | Code: MRS - 51374

The report covers forecast and analysis for the cancer diagnostics market on a global and regional level. The study provides historic data of 2014 along with a forecast from 2015 to 2020 based revenue (USD Billion). The study includes drivers and restraints for the cancer diagnostics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the cancer diagnostics market on a global level.

In order to give the users of this report a comprehensive view on the cancer diagnostics. To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the cancer diagnostics market has also been included. The study encompasses a market attractiveness analysis, wherein methods segments and application segments are benchmarked based on their market size, growth rate and general attractiveness.

The study provides a decisive view on the cancer diagnostics market by segmenting the market based on methods of diagnostics, applications and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2014 to 2020. Based on methods the market is segmented into tumor biomarker tests, imaging, endoscopy, and biopsy. Key application market covered under this study includes blood cancer, breast cancer, colorectal cancer (CRC), kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, and prostate cancer. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East and Africa with its further bifurcation into major countries including U.S. Germany, France, UK, China, Japan, India and Brazil. This segmentation includes demand for cancer diagnostics based on individual applications in all the regions and countries.

The report also includes detailed profiles of end players such as Abbott Laboratories, Inc., Ambry Genetics, AstraZeneca plc, bioMeriux SA, Eli Lilly and Company, Genoptix, Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., and Pfizer, Inc. The detailed description of players includes parameters such as company overview, financial overview, business and recent developments of the company.

This report segments the global cancer diagnostics market as follows:

Global Cancer Diagnostics Market: Methods Segment Analysis

  • Tumor Biomarker Tests
  • Imaging
  • Endoscopy
  • Biopsy

Global Cancer Diagnostics Market: Application Segment Analysis

  • Blood Cancer
  • Breast Cancer
  • Colorectal Cancer (CRC)
  • Lung Cancer
  • Others

Global Cancer Diagnostics Market: Regional Segment Analysis

  • North America
    • U.S.
  • Europe
    • Germany
    • France
    • UK
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa
  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global cancer diagnostics market, 2014 - 2020 (USD Billion)
    • 2.2. Global cancer diagnostics market : Snapshot
  • Chapter 3. Cancer Diagnostics – Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global cancer diagnostics market drivers: Impact analysis
      • 3.2.2. Increasing prevalence of cancer
      • 3.2.3. Technological advancements
      • 3.2.4. Initiatives undertaken by governments and global health organizations to spread awareness about cancer
      • 3.2.5. Increasing number of private diagnostic centers
    • 3.3. Market restraints
      • 3.3.1. Global cancer diagnostics market restraints: Impact analysis
      • 3.3.2. Lack of sensitivity and specificity
      • 3.3.3. Risk of high radiation exposure used in different treatments
    • 3.4. Opportunities
      • 3.4.1. Safe cancer screening methods due to technology advancements
    • 3.5. Porter’s five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by methods segment
      • 3.6.2. Market attractiveness analysis, by application segment
      • 3.6.3. Market attractiveness analysis, by regional segment
  • Chapter 4. Global Cancer diagnostics Market – Competitive Landscape
    • 4.1. Company market share, 2014
    • 4.2. Price trend analysis
  • Chapter 5. Global Cancer diagnostics Market – Method Segment Analysis
    • 5.1. Global cancer diagnostics market: Method overview
      • 5.1.1. Global cancer diagnostics market revenue share, by method, 2014 and 2020
    • 5.2. Tumor Biomarker Tests
      • 5.2.1. Global tumor biomarker tests market, 2014 – 2020 (USD Billion)
    • 5.3. Imaging
      • 5.3.1. Global imaging market, 2014 – 2020 (USD Billion)
    • 5.4. Endoscopy
      • 5.4.1. Global endoscopy market , 2014 – 2020 (USD Billion)
    • 5.5. Biopsy
      • 5.5.1. Global biopsy market , 2014 – 2020 (USD Billion)
  • Chapter 6. Global Cancer diagnostics Market – Application Segment Analysis
    • 6.1. Global cancer diagnostics market: Application overview
      • 6.1.1. Global cancer diagnostics market revenue share, by application, 2014 and 2020
    • 6.2. Blood Cancer
      • 6.2.1. Global cancer diagnostics market for blood cancer, 2014 – 2020 (USD Billion)
    • 6.3. Breast Cancer
      • 6.3.1. Global cancer diagnostics market for breast cancer, 2014 – 2020 (USD Billion)
    • 6.4. Colorectal Cancer (CRC)
      • 6.4.1. Global cancer diagnostics market for colorectal cancer (CRC), 2014 – 2020 (USD Billion)
    • 6.5. Kidney Cancer
      • 6.5.1. Global cancer diagnostics market for kidney cancer, 2014 – 2020 (USD Billion)
    • 6.6. Liver Cancer
      • 6.6.1. Global cancer diagnostics market for liver cancer, 2014 - 2020(USD Billion)
    • 6.7. Lung Cancer
      • 6.7.1. Global cancer diagnostics market for lung cancer, 2014 – 2020 (USD Billion)
    • 6.8. Ovarian Cancer
      • 6.8.1. Global cancer diagnostics market for ovarian cancer, 2014 - 2020(USD Billion)
    • 6.9. Pancreatic Cancer
      • 6.9.1. Global cancer diagnostics market for pancreatic cancer, 2014 – 2020 (USD Billion)
    • 6.10. Prostate Cancer
      • 6.10.1. Global cancer diagnostics market for prostate cancer, 2014 – 2020 (USD Billion)
  • Chapter 7. Global Cancer diagnostics Market – Regional Segment Analysis
    • 7.1. Global cancer diagnostics market: Regional overview
      • 7.1.1. Global cancer diagnostics market revenue share, by region, 2014 and 2020
    • 7.2. North America
      • 7.2.1. North America cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
      • 7.2.2. North America cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
      • 7.2.3. U.S.
        • 7.2.3.1. U.S. cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
        • 7.2.3.2. U.S. cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
    • 7.3. Europe
      • 7.3.1. Europe cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
      • 7.3.2. Europe cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
      • 7.3.3. Germany
        • 7.3.3.1. Germany cancer diagnostics market revenue, by methods, 2014 – 2020, (USD Billion)
        • 7.3.3.2. Germany cancer diagnostics market revenue, by application, 2014 – 2020, (USD Billion)
      • 7.3.4. France
        • 7.3.4.1. France cancer diagnostics market revenue, by methods, 2014 – 2020, (USD Billion)
        • 7.3.4.2. France cancer diagnostics market revenue, by application, 2014 – 2020, (USD Billion)
      • 7.3.5. UK
        • 7.3.5.1. UK cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
        • 7.3.5.2. UK cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific cancer diagnostics market revenue, by methods, 2014 – 2020, (USD Billion)
      • 7.4.2. Asia Pacific cancer diagnostics market revenue, by application, 2014 – 2020, (USD Billion)
      • 7.4.3. China
        • 7.4.3.1. China cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
        • 7.4.3.2. China cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
      • 7.4.4. Japan
        • 7.4.4.1. Japan cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
        • 7.4.4.2. Japan cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
      • 7.4.5. India
        • 7.4.5.1. India cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
        • 7.4.5.2. India cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
    • 7.5. Latin America
      • 7.5.1. Latin America cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
      • 7.5.2. Latin America cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
        • 7.5.3.2. Brazil cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
    • 7.6. Middle East and Africa
      • 7.6.1. Middle East and Africa cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
      • 7.6.2. Middle East and Africa cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
  • Chapter 8. Company Profile
    • 8.1. Abbott Laboratories, Inc.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Ambry Genetics
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. AstraZeneca plc
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. bioMeriux SA
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. Eli Lilly and Company
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Genoptix, Inc.
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. GlaxoSmithKline plc
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. F. Hoffmann-La Roche Ltd.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Product portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. Pfizer, Inc.
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Product portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments

List of Tables

1. Cancer diagnostics  market: Market snapshot                                  
2. Drivers of global cancer diagnostics  market: Impact analysis
3. Restraints of global cancer diagnostics  market: Impact analysis  
4. North America cancer diagnostics  market revenue, by methods, 2014 - 2020 (USD Billion)
5. North America cancer diagnostics  market revenue, by application, 2014 - 2020 (USD Billion)
6. U.S. cancer diagnostics  market revenue, by methods, 2014 - 2020 (USD Billion)
7. U.S. cancer diagnostics  market revenue, by application, 2014 - 2020 (USD Billion)
8. Germany cancer diagnostics  market revenue, by methods, 2014 - 2020 (USD Billion)
9. Germany cancer diagnostics  market revenue, by application, 2014 - 2020 (USD Billion)
10. France cancer diagnostics  market revenue, by methods, 2014 - 2020 (USD Billion)
11. France cancer diagnostics  market revenue, by application, 2014 - 2020 (USD Billion)
12. UK cancer diagnostics  market revenue, by methods, 2014 - 2020 (USD Billion)
13. UK cancer diagnostics  market revenue, by application, 2014 - 2020 (USD Billion)
14. Asia Pacific cancer diagnostics  market revenue, by methods, 2014 - 2020 (USD Billion)
15. Asia Pacific cancer diagnostics  market revenue, by application, 2014 - 2020 (USD Billion)
16. China cancer diagnostics  market revenue, by methods 2014 - 2020 (USD Billion)
17. China cancer diagnostics  market revenue, by application 2014 - 2020 (USD Billion)
18. Japan cancer diagnostics  market revenue, by methods, 2014 - 2020 (USD Billion)
19. Japan cancer diagnostics  market revenue, by application, 2014 - 2020 (USD Billion)
20. India cancer diagnostics  market revenue, by methods, 2014 - 2020 (USD Billion)
21. India cancer diagnostics  market revenue, by application, 2014 - 2020 (USD Billion)
22. Latin America cancer diagnostics  market revenue, by methods, 2014 - 2020 (USD Billion)
23. Latin America cancer diagnostics  market revenue, by application, 2014 - 2020 (USD Billion)
24. Brazil cancer diagnostics  market revenue, by methods, 2014 - 2020 (USD Billion)
25. Brazil cancer diagnostics  market revenue, by application, 2014 - 2020 (USD Billion)
26. Middle East and Africa cancer diagnostics  market revenue, by methods, 2014 - 2020 (USD Billion)
27. Middle East and Africa cancer diagnostics market revenue, by application, 2014 - 2020 (USD Billion)


List of Figures

1. Market research process
2. Market research methodology
3. Global cancer diagnostics  market revenue, 2014 - 2020 (USD Billion)
4. Porter’s five forces analysis
5. Cancer diagnostics : Market attractiveness analysis, by methods segment
6. Cancer diagnostics : Market attractiveness analysis, by application segment
7. Cancer diagnostics : Market attractiveness analysis, by regional segment
8. Company market share analysis, 2014 and 2020
9. Global cancer diagnostics  market revenue share by application, 2014 and 2020
10. Global  cancer diagnostics  market for blood cancer, 2014 – 2020, (USD Billion)
11. Global  cancer diagnostics  market for breast cancer, 2014 – 2020, (USD Billion)
12. Global cancer diagnostics  market for  colorectal cancer (CRC), 2014 – 2020, (USD Billion)
13. Global cancer diagnostics  market for kidney cancer, 2014 – 2020, (USD Billion)
14. Global cancer diagnostics  market for liver cancer, 2014 – 2020, (USD Billion)
15. Global cancer diagnostics  market for lung cancer, 2014 – 2020, (USD Billion)   
16. Global cancer diagnostics  market for ovarian cancer, 2014 – 2020, (USD Billion)   
17. Global cancer diagnostics  market for pancreatic cancer, 2014 – 2020, (USD Billion)
18. Global cancer diagnostics  market for prostate cancer, 2014 – 2020, (USD Billion)  

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields


Zion Research uses the synergy of combination of both primary research and secondary research for its research reports. For this study, we have conducted extensive primary research, wherein we have conducted in-depth interviews of the key opinion leader of this industry. Primary research make up for the biggest chunk of our data sources in addition to secondary research.

We referred to product literature of leading industry participants, annual reports, press releases, government publications, and other relevant sources for data collection and analysis thereof. Secondary research also includes a search of recent trade journals, technical writing, internet sources, and statistical data from government websites, trade associations and agencies.  

Zion Research has collected key data related to the Cancer Diagnostics Market and analyzed these data using a variety of methods. The market dynamics have been ascertained following a detailed study of the micro, meso, and macroeconomic indicators of the market.

This report is based on in-depth qualitative and quantitative analyses of the Global Cancer Diagnostics Market. The quantitative analysis involved the application of various projection and sampling techniques. The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions.

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically partake in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Based on the research results and technical insights thus gathered, Zion research analysts have provided a comprehensive analysis of the varied aspects of the market. The impact of global economic conditions and other macroeconomic indicators was also considered when assessing the market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Cancer is a disease in which uncontrolled growth of cells form a tumor. It also called as malignancy. Rising number of cancer patients worldwide and increasing healthcare expenditure are expected to support the global cancer diagnostics market. Not all the cancer has potential of spreading to other parts of the body. There are two types of tumors namely cancerous or malignant (spreads throughout the body) and benign tumors or static tumors which do not spread to other body parts. Some commonly occurring symptoms in cancer are prolonged cough, new lump, weight loss and abnormal bleeding. Cancer diagnostic deals with the management of cancer by providing a wide range of high-value tools for screening, diagnosis and monitoring of different types of cancer. It is used to detect the cancer and also performs different treatments.

Cancer diagnostics market is mainly driven by technological advancements, huge funds, and investments across the world. Use of microscopy devices has become necessary to prepare required sample. Rapid progress in technology is another important factor that has been resulted into growing exploitation for microscopy devices. The safe cancer screening methods due to technology advancements provide future growth opportunity to industry participants. Cancer is a genetic disorder and increasing prevalence of cancer, growing development in new DNA sequencing and next generation sequencing technologies is expected to trigger the growth of this industry in the coming years across the globe.

Cancer Diagnostics Market

On the basis of method, the global cancer diagnostics market is divided into tumor biomarker tests, endoscopy, imaging, and biopsy. The cancer imaging method of cancer diagnosis is the fastest growing segment of cancer diagnosis market. The imaging sector dominated the cancer diagnostics market and it accounted for significant market share of the total market in 2014.

On the basis of applications, the cancer diagnostics market has been segmented as blood cancer, breast cancer, colorectal cancer (CRC), kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer. Breast cancer applications segment dominated the global cancer diagnostics market and accounted for major share of the entire market in 2014. Lung cancer and colorectal cancer are emerging as lucrative segments of the cancer diagnostics market and expected to grow at a strong CAGR during the forecast period.

North America was the leading regional market for global cancer diagnostics and accounted for over 40.7% share of the total market in 2014. It also expected to continue this development by the end of 2020 due to rising advancement in technology associated with the methods and treatments of cancer. North America is followed by Europe. The Asia Pacific cancer diagnostics market is driven by the increasing prevalence of breast cancer in this region.

Abbott Laboratories, Inc., Ambry Genetics, AstraZeneca plc, bioMeriux SA, Eli Lilly and Company, Genoptix, Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., and Pfizer, Inc are some of the key vendors in the market.

  • Payment Mode
Single User | $(USD)4199 View Pricing